Takecab tablets 20 mg for ulcers and reflux (vonoprazan fumarate)
What are Takecab tablets 20 mg for ulcers and reflux (vonoprazan fumarate)?
Takecab tablets, containing vonoprazan fumarate, are commonly prescribed medications used in the management of gastrointestinal conditions characterized by excessive gastric acid secretion, primarily targeting gastric/duodenal ulcers and reflux esophagitis. The mechanism of action of Takecab involves the inhibition of the proton pump in a potassium ion-competitive manner, which effectively reduces the secretion of gastric acid within the stomach.
Gastric and duodenal ulcers are often associated with excessive acid production within the stomach lining. Vonoprazan fumarate, the active ingredient in Takecab, acts as a potent and long-lasting inhibitor of the proton pump, responsible for acid secretion in parietal cells. By selectively binding to the potassium-ion binding site on the proton pump, Takecab prevents the final step in acid production, resulting in a significant decrease in gastric acid output.
Reflux esophagitis, characterized by the inflammation of the esophagus due to the backflow of stomach acid, is also effectively managed with Takecab tablets. The reduced gastric acid secretion alleviates symptoms and promotes the healing of esophageal tissues damaged by acid exposure.
Furthermore, Takecab is employed for the suppression of recurrence of gastric/duodenal ulcers, particularly in cases associated with low-dose aspirin or nonsteroidal anti-inflammatory drug (NSAID) medication. NSAIDs and aspirin use can often lead to irritation and ulcers in the stomach and duodenum, but Takecab's mechanism of action helps mitigate the risk of ulcer recurrence by maintaining a lower acidic environment.
Clinical studies and trials have demonstrated the effectiveness of Takecab tablets in achieving symptom relief and promoting the healing of ulcers and esophageal damage caused by reflux. Its potassium ion-competitive inhibition mechanism has shown promising results in reducing gastric acid secretion, which can be especially beneficial for patients suffering from these conditions.
Active principles: vonoprazan fumarate
Amount: 100 tablets
Maker: Takeda Pharmaceutical Co. Ltd., Tokyo, Japan
- treatment of gastric ulcer,
- treatment of the duodenal ulcer,
- treatment of reflux esophagitis,
- suppression of recurrence of gastric/duodenal ulcer associated with low-dose aspirin or nonsteroidal anti-inflammatory drug medication.
How to take
For gastric or duodenal ulcer or reflux esophagitis: adults should take 1 tablet (20 mg of vonoprazan) at a time, once a day. Duration of the treatment should be within 8 weeks for gastric ulcer, 6 weeks for duodenal ulcer, 4 weeks for reflux esophagitis (if the effect is insufficient, the treatment for reflux esophagitis may be continued for up to 8 weeks).
Maintenance therapy for repeatedly relapsing reflux esophagitis: adults should take 0.5 tablet (10 mg of vonoprazan) at a time, once a day. If the effect is insufficient, your doctor may increase the dosage to 1 tablet (20 mg) at a time.
Suppression of recurrence of gastric or duodenal ulcers associated with low-dose aspirin or non-steroidal anti-inflammatory drug therapy: adults should take 0.5 tablet (10 mg) at a time, once a day.
Contraindications: do not use for patients with liver or renal disorder. Do not use for pregnant or breastfeeding women.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.